Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer

被引:60
作者
Campos, Ximena
Munoz, Yenny
Selman, Alberto
Yazigi, Roberto
Moyano, Leonor
Weinstein-Oppenheimer, Caroline
Lara, Hernan E.
Romero, Carmen
机构
[1] Univ Chile, Hosp Clin, Dept Obstet & Ginecol, Lab Endocrinol & Biol Reprod, Santiago, Chile
[2] Univ Chile, Fac Med, Dept Obstet & Ginecol, Santiago, Chile
[3] Univ Chile, Hosp Clin, Serv Anat Patol, Santiago, Chile
[4] Univ Valparaiso, Fac Farm, Dept Bioquim, Valparaiso, Chile
[5] Univ Chile, Fac Ciencias Quim & Farmaceut, Lab Neurobioquim, Santiago, Chile
关键词
NGF; trkA; VEGF; epithelial ovarian cancer;
D O I
10.1016/j.ygyno.2006.07.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To compare the expression of nerve growth factor (NGF) and its high-affinity receptor trkA in normal ovaries and in epithelial ovarian carcinomas. Given NGF acts as an angiogenic factor through a vascular endothelial growth factor (VEGF)-mediated mechanism in several types of tissues, we examined whether NGF regulates the expression of VEGF isoforms in epithelial ovarian cancer (EOC). Methods. The expression and localization of NGF and tyrosine kinase receptor A (trkA) in normal ovarian samples and in ovarian cancer samples were analyzed by RT-PCR and immumohistochemistry. NGF regulates the expression of three VEGF isoforms (VEGF(121), VEGF(165) and VEGF(189)); these were examined using RT-PCR in explants of EOC and ELISA in culture media. Results. TrkA mRNA levels were over-expressed in ovarian cancer compared to normal ovarian samples, whereas NGF mRNA levels remained unchanged. NGF and trkA proteins were absent or found in very low levels in normal ovarian surface epithelium (OSE), whereas they were highly expressed in epithelial cells of EOC. Additionally, NGF stimulated the expression of VEGF isoforms in cancer explants. The effect was dose-dependent and inhibited by a NGF antibody and by K-252a, a trk receptor inhibitor. Conclusion. The abundance of NGF and trkA receptors in epithelial cells of EOC, together with the ability of NGF to increase VEGF expression strongly suggests an autocrine role of NGF in EOC. These findings suggest that blocking neurotrophin action could be a therapeutic target in treating ovarian cancer. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 175
页数:8
相关论文
共 50 条
[1]   Presence of NGF and its receptors in ovaries from human fetuses and adults [J].
Abir, R ;
Fisch, B ;
Jin, S ;
Barnnet, M ;
Ben-Haroush, A ;
Felz, C ;
Kessler-Icekson, G ;
Feldberg, D ;
Nitke, S ;
Ao, A .
MOLECULAR HUMAN REPRODUCTION, 2005, 11 (04) :229-236
[2]   Angiogenesis of the ovary [J].
Abulafia, O ;
Sherer, DM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (01) :240-246
[3]  
ANDERSON RA, 2005, MOL HUM REPROD, V1, P79
[4]   Angiogenesis in ovarian cancer [J].
Brown, MR ;
Blanchette, JO ;
Kohn, EC .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2000, 14 (06) :901-918
[5]   Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors [J].
Calzà, L ;
Giardino, L ;
Giuliani, A ;
Aloe, L ;
Levi-Montalcini, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (07) :4160-4165
[6]   Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo [J].
Cantarella, G ;
Lempereur, L ;
Presta, M ;
Ribatti, D ;
Lombardo, G ;
Lazarovici, P ;
Zappalà, G ;
Pafumi, C ;
Bernardini, R .
FASEB JOURNAL, 2002, 16 (08) :1307-+
[7]   IMMUNOHISTOCHEMICAL ANALYSIS OF NERVE GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL AND MALIGNANT HUMAN-TISSUES [J].
CHESA, PG ;
RETTIG, WJ ;
THOMSON, TM ;
OLD, LJ ;
MELAMED, MR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1988, 36 (04) :383-389
[8]   Improving ischaemic skin revascularisation by nerve growth factor in a child with crush syndrome [J].
Chiaretti, A ;
Piastra, M ;
Caresta, E ;
Nanni, L ;
Aloe, L .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (05) :446-448
[9]  
CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717
[10]  
Davidson B, 2003, CLIN CANCER RES, V9, P2248